These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 35377160)
1. Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. Selvaraj S; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Juliano RA; Jiao L; Tardif JC; Ballantyne CM; J Am Heart Assoc; 2022 Apr; 11(7):e024999. PubMed ID: 35377160 [TBL] [Abstract][Full Text] [Related]
2. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Majithia A; Bhatt DL; Friedman AN; Miller M; Steg PG; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Budoff M; Preston Mason R; Tardif JC; Boden WE; Ballantyne CM Circulation; 2021 Nov; 144(22):1750-1759. PubMed ID: 34706555 [TBL] [Abstract][Full Text] [Related]
3. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM; J Am Heart Assoc; 2022 Mar; 11(6):e022937. PubMed ID: 35261279 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM; N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628 [TBL] [Abstract][Full Text] [Related]
5. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Verma S; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Dhingra NK; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Mason RP; Tardif JC; Ballantyne CM; Circulation; 2021 Dec; 144(23):1845-1855. PubMed ID: 34710343 [TBL] [Abstract][Full Text] [Related]
6. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM; J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607 [TBL] [Abstract][Full Text] [Related]
8. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT. Burger PM; Bhatt DL; Dorresteijn JAN; Koudstaal S; Mosterd A; Martens FMAC; Steg PG; Visseren FLJ; Eur Heart J Cardiovasc Pharmacother; 2024 Oct; 10(6):488-499. PubMed ID: 38678009 [TBL] [Abstract][Full Text] [Related]
9. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Chapman MJ; Zamorano JL; Parhofer KG Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222 [TBL] [Abstract][Full Text] [Related]
10. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Bhatt DL; Miller M; Brinton EA; Jacobson TA; Steg PG; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Olshansky B; Chung MK; Gibson CM; Giugliano RP; Budoff MJ; Ballantyne CM; Circulation; 2020 Feb; 141(5):367-375. PubMed ID: 31707829 [TBL] [Abstract][Full Text] [Related]
11. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Miller M; Tardif JC; Ketchum SB; Doyle RT; Murphy SA; Soni PN; Braeckman RA; Juliano RA; Ballantyne CM; Clin Cardiol; 2017 Mar; 40(3):138-148. PubMed ID: 28294373 [TBL] [Abstract][Full Text] [Related]
12. Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry. Picard F; Bhatt DL; Ducrocq G; Ohman EM; Goto S; Eagle KA; Wilson PWF; Smith SC; Elbez Y; Steg PG Int J Cardiol; 2021 Oct; 340():96-104. PubMed ID: 34450192 [TBL] [Abstract][Full Text] [Related]
13. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT. Gaba P; Bhatt DL; Mason RP; Miller M; Verma S; Steg PG; Boden WE; J Clin Lipidol; 2022; 16(4):389-402. PubMed ID: 35773147 [TBL] [Abstract][Full Text] [Related]
14. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Ridker PM; Rifai N; MacFadyen J; Glynn RJ; Jiao L; Steg PG; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Mason RP; Bhatt DL Circulation; 2022 Aug; 146(5):372-379. PubMed ID: 35762321 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT. Olshansky B; Bhatt DL; Miller M; Steg PG; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Kowey PR; Reiffel JA; Tardif JC; Ballantyne CM; Chung MK; J Am Heart Assoc; 2023 Mar; 12(5):e026756. PubMed ID: 36802845 [TBL] [Abstract][Full Text] [Related]
17. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081 [TBL] [Abstract][Full Text] [Related]
18. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118 [TBL] [Abstract][Full Text] [Related]
19. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Orringer CE; Jacobson TA; Maki KC J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586 [TBL] [Abstract][Full Text] [Related]
20. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking. Miller M; Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Jiao L; Tardif JC; Ballantyne CM; Budoff M; Mason RP Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):129-137. PubMed ID: 35953437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]